Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...

On Friday, Geron Corp (GERN) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.14 or 3.16% from the prior close of $4.43. The stock opened at $4.47 and ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.6 which represents a slight increase of $0.06 or 3.90% from the prior close of $1.54. The stock opened at ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock.

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock. The ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...